New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation ...
Apr 25, 2015
0
7
Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with ...
Apr 25, 2015
0
5
Study results presented today at The International Liver Congress 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.
Apr 25, 2015
0
5
An over-the-counter drug indicated to treat allergy symptoms limited hepatitis C virus activity in infected mice, according to a National Institutes of Health study. The results suggest that the drug, chlorcyclizine HCl (CCZ), ...
Apr 8, 2015
0
102
The drug combination of ledipasvir and sofosbuvir (trade name Harvoni) has been available since November 2014 for the treatment of chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care ...
Mar 9, 2015
0
7
(HealthDay)—Two cases of hepatitis C infection that occurred during routine surgeries highlight the need for hospitals to tighten infection control to prevent more transmissions, officials said Friday.
Mar 2, 2015
0
3
Hepatitis C virus infection is a common cause of liver disease and of liver cancer in the United States. Through a new study that explores one aspect of how the virus hijacks host cell machinery to replicate itself, UNC Lineberger ...
Feb 23, 2015
0
9
More than 180 million people in the world have hepatitis C, compared with the 34 million with HIV/AIDS and the roughly 30,000 who have had Ebola. Yet very little is heard about the hepatitis C virus (HCV) in the way of awareness ...
Feb 4, 2015
0
12
(HealthDay)—Many hepatitis C patients get "lost" in the U.S. health care system, a new study suggests.
Jan 11, 2015
0
42
A 24-week course of sofosbuvir and ribavirin can eliminate hepatitis C virus (HCV) infection in two-thirds of patients who undergo liver transplantation, with positive consequences on their short- and long-term prognoses, ...
Jan 9, 2015
0
7
